Zhenfang F. Liu

No. 6, Shuang Yong Road
Nanning, 530021, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

METTL14-mediated m6A modification of CCNE1 accelerates progression of myelodysplastic syndromes via MAPK-ERK and PI3K-AKT signaling pathways.

METTL14-mediated m6A modification of CCNE1 accelerates progression of myelodysplastic syndromes via MAPK-ERK and PI3K-AKT signaling pathways.

Journal: Cellular signalling

Published: March 17, 2026

Interplay Between Psychological Burden, Economic Stress, and Quality of Life in Chronic Myeloid Leukemia Care: An Integrated Analysis.

Interplay Between Psychological Burden, Economic Stress, and Quality of Life in Chronic Myeloid Leukemia Care: An Integrated Analysis.

Journal: JCO oncology practice

Published: March 10, 2026

Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study.

Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 07, 2026

Iron-vacancy-tailored sonosensitive catalysts amplify noninvasive tumor suppression by apoptosis/pyroptosis co-induction.

Iron-vacancy-tailored sonosensitive catalysts amplify noninvasive tumor suppression by apoptosis/pyroptosis co-induction.

Journal: Biomaterials

Published: December 07, 2025

Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia.

Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: November 05, 2025

ITPR2 Promotes Acute Myeloid Leukemia Progression Through Calcium-Mediated Mitochondrial Dysfunction.

ITPR2 Promotes Acute Myeloid Leukemia Progression Through Calcium-Mediated Mitochondrial Dysfunction.

Journal: Frontiers in bioscience (Landmark edition)

Published: October 30, 2025

Imatinib and nilotinib are equally successful in achieving therapy-free remission.

Imatinib and nilotinib are equally successful in achieving therapy-free remission.

Journal: Blood cancer journal

Published: October 22, 2025

Venetoclax and Homoharringtonine-Based Therapy Exhibited a Striking Response in Refractory/Relapsed Early T-Cell Precursor Acute Lymphoblastic Leukemia.

Venetoclax and Homoharringtonine-Based Therapy Exhibited a Striking Response in Refractory/Relapsed Early T-Cell Precursor Acute Lymphoblastic Leukemia.

Journal: MedComm

Published: July 09, 2025

Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure.

Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure.

Journal: British journal of haematology

Published: June 14, 2025

Olverembatinib for 8p11 myeloproliferative syndrome with a positive BCR-FGFR1 fusion gene: a case report.

Olverembatinib for 8p11 myeloproliferative syndrome with a positive BCR-FGFR1 fusion gene: a case report.

Journal: Annals of hematology

Published: June 05, 2025

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.

Journal: Haematologica

Published: May 15, 2025

Machine learning-based prognostic model for bloodstream infections in hematological malignancies using Th1/Th2 cytokines.

Machine learning-based prognostic model for bloodstream infections in hematological malignancies using Th1/Th2 cytokines.

Journal: BMC infectious diseases

Published: February 11, 2025

Showing 1-12 of 55

Last Updated: 09/26/2026